Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome

Journal of Diabetes

Volumn 2, Issue 3, 2010, Pages 146-156

  Jones, T Hugh ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

atherosclerosis; dyslipidemia; erectile dysfunction; hypertension; insulin resistance; metabolic syndrome; obesity; testosterone; Type 2 diabetes

Indexed keywords

ANDROSTANOLONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TESTOSTERONE ENTHANOATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; TESTOSTERONE;

EID: 77955822370     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2010.00085.x     Document Type: Review

References (74)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 285 : 2486 97.
2. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from: http://www.idf.org/webdata/docs/IDF- Meta-def-final.pdf (accessed 11 July 2009).
3. Kapoor D, Aldred H, Clark S et al. Clinical and biochemical assessment of hypogonadism in men with Type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007 30 : 911 7.
4. Wang C, Nieschlag E, Swerdloff R et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009 30 : 1 9.
5. Haffner SM, Karhapää P, Mykkänen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994 43 : 212 9.
6. Simon D, Charles MA, Nahoul K et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997 82 : 682 5.
7. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of Type 2 diabetes. JAMA. 2006 295 : 1288 99.
8. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in Type 2 diabetes. J Clin Endocrinol Metab. 2004 89 : 5462 8.
9. Oh JY, Barrett-Connor E, Wedick NM et al. Endogenous sex hormones and the development of Type 2 diabetes in older men and women. Diabetes Care. 2002 25 : 55 60.
10. Stellato RK, Feldman HA, Hamdy O et al. Testosterone, sex hormone binding globulin and the development of Type 2 diabetes in middle aged men. Diabetes Care. 2000 23 : 490 4.
11. Haffner SM, Shaten J, Stern MP et al. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol. 1996 143 : 889 97.
12. Chandel A, Chaudhuri A, Dhindsa S et al. Testosterone concentration in young patients with diabetes. Diabetes Care. 2008 31 : 2013 7.
13. Zumoff B, Strain GW, Miller LK et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990 71 : 929 31.
14. Pasquali R, Casimirri F, Cantobelli S et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991 40 : 101 4.
15. Seidell JC, Bjorntorp P, Sjostrom L et al. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism. 1990 39 : 897 901.
16. Haffner SM, Valdez RA, Stern MP et al. Obesity, body fat distribution and sex hormones in men. Int J Obes. 1993 17 : 643 9.
17. Phillips GB. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism. 1993 42 : 116 20.
18. Abate N, Haffner SM, Garg A et al. Sex steroid hormones, upper body obesity and insulin resistance. J Clinl Endocrinol Metab. 2002 87 : 4522 7.
19. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest. 1999 22 : 110 6.
20. Dhindsa S, Bhatia V, Dhindsa G et al. The effects of hypogonadism on body composition and bone mineral density in Type 2 diabetic patients. Diabetes Care. 2007 30 : 1860 1.
21. Cohen PG. The hypogonadal-obesity cycle. Med Hypotheses. 1999 52 : 49 51.
22. Singh R, Artaza JN, Taylor WE et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T12 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003 144 : 5081 8.
23. Jones TH. Testosterone associations with erectile dysfunction, diabetes and metabolic syndrome. Eur Urol Suppl. 2007 6 : 847 57.
24. Pitteloud N, Hardin M, Dwyer AA et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005 90 : 2636 41.
25. Bruning JC, Gantam D, Burks DJ et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000 14 : 1000 5.
26. Van Pottelbergh I, Braeckman L, De Bacquer D et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003 166 : 95 102.
27. Stanworth RD, Kapoor D, Channer KS et al. Testosterone levels correlate positively with HDL cholesterol levels in men with Type 2 diabetes. Endocrine Abstr. 2007 14 : P628.
28. Svartberg J, von Muehlen D, Schirmer H et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø study. Eur J Endocrinol. 2004 150 : 65 71.
29. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988 6 : 329 32.
30. Messerli FH, Garavaglia GE, Schmieder RE et al. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987 107 : 158 61.
31. Bocchi EA, Carvalho VO, Guimaraes GV. Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Int Braz J Urol. 2008 34 : 302 10.
32. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009 207 : 318 27.
33. Yialamas MA, Dwyer AA, Hanley E et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007 92 : 4254 9.
34. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008 108 : 272 80.
35. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord. 2000 24 (Suppl. 2 S59 63.
36. Singh AB, Hsia S, Alaupovic P et al. The effects of varying doses of testosterone on insulin sensitivity, plasma lipids, apolipoproteins and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002 87 : 136 43.
37. Pitteloud N, Mootha VK, Dwyer AA et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005 28 : 1636 42.
38. Ghanim H, Aljada A, Daoud N et al. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia. 2007 60 : 278 85.
39. Isidori AM, Gianetta E, Greco EA et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle aged men: a meta-analysis. Clin Endocrinol. 2005 63 : 280 93.
40. Maravelias C, Dona A, Stefanidou M et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett. 2005 158 : 167 75.
41. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 14 : 55 69.
42. Sullivan ML, Martinez CM, Gennis P et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998 41 : 1 15.
43. Marin P, Holmang S, Gustafsson C et al. Androgen treatment of abdominally obese men. Obes Res. 1993 1 : 245 51.
44. Andersen FH, Francis RM, Faulkner KF. Androgen supplementation in eugonadal men with osteoporosis effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996 18 : 171 7.
45. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007 92 : 3844 53.
46. Corrales JJ, Almeida M, Burgo R et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol. 2006 189 : 595 604.
47. Malkin CJ, Pugh PJ, Jones RD et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 89 : 3313 8.
48. Malkin CJ, Pugh PJ, Morris PD et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 90 : 871 6.
49. Guler N, Batyraliev T, Dulger H et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol. 2006 109 : 339 43.
50. Kapoor D, Clarke S, Stanworth R et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with Type 2 diabetes. Eur J Endocrinol. 2007 156 : 595 602.
51. Bhatia V, Chaudhuri A, Tomar R et al. Low testosterone and high C-reactive protein concentrations predict low haematocrit in Type 2 diabetes. Diabetes Care. 2006 29 : 2289 94.
52. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001 111 : 261 9.
53. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with Type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 6 : 1 7.
54. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with Type 2 diabetes. Eur J Endocrinol. 2006 154 : 899 906.
55. Heufelder AE, Saad F, Mathijs C, Gooren L. 52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycaemic control in men with newly diagnosed Type 2 diabetes and subnormal plasma testosterone. J Androl. 2009 30 : 726 33.
56. Jones H, Howell J, Channer K. Testosterone improves glycaemic control, insulin resistance, body fat and sexual function in men with metabolic syndrome andor type 2 diabetes: a multicentre European clinical trial. The TIMES2 study. Endocrine Abstr. 2010 21 : OC1.
57. Rebuffe-Scrive M, Marin P, Bjorntrop P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 1991 15 : 791 5.
58. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992 75 : 1092 8.
59. Marin P. Testosterone and regional fat distribution. Obes Res. 1995 3 (Suppl. S609 12.
60. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999 84 : 2647 53.
61. Kenny AM, Prestwood KM, Gruman CA et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001 56 : M266 73.
62. Simon D, Charles MA, Lahlou N et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care. 2001 24 : 2149 51.
63. Naharci MI, Pinar M, Bolu E et al. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007 13 : 629 35.
64. Saad F, Gooren L, Haider A et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007 53 : 353 7.
65. Saad F, Gooren LJ, Haider A et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008 29 : 102 5.
66. Agledahl I, Hansen JB, Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest. 2008 11 : 1 8.
67. Allan CA, Strauss BJG, Burger HG et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab. 2008 93 : 139 46.
68. Thompson PD, Cullinane EM, Sady SP et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Assoc. 1989 261 : 1165 8.
69. Bagatell CJ, Heiman JR, Matsumoto AM et al. Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994 79 : 561 7.
70. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996 121 : 35 43.
71. Uyanik BS, Ari Z, Gumus B et al. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J. 1997 38 : 73 82.
72. Tripathy D, Shah P, Lakshmy R et al. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotropic hypogonadism. Horm Metab Res. 1998 30 : 642 5.
73. Howell SJ, Radford JA, Adams JE et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol. 2001 55 : 315 24.
74. Ly LP, Jimenez M, Zhuang TN et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001 86 : 4078 88.